Last checked at 9 Feb 2024 09:15
LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat
AZN Share
Trades18,291
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
11,988.00
Bid:
12,016.00
Ask:
12,020.00
Change:
-38.00 (-0.32%)
Spread:
4.00 (0.033%)
Open:
12,070.00
High:
12,144.00
Low:
11,882.00
Prev. Close:
12,026.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.AstraZeneca's Imfinzi fails to reach endpoint in difficult trial
Fri, 07th Dec 2018 07:24
(Sharecast News) - AstraZeneca and its global biologics research and development arm MedImmune announced overall survival results for the Phase III EAGLE trial of Imfinzi (durvalumab) on Friday.The FTSE 100 pharmaceutical behemoth described EAGLE as a randomised, open-label, multi-centre trial evaluating Imfinzi monotherapy or Imfinzi in combination with tremelimumab - an anti-CTLA4 antibody - compared to standard-of-care chemotherapy, in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who experienced disease progression following platinum-based chemotherapy, regardless of their PD-L1 tumour status.It said Imfinzi monotherapy and the combination of Imfinzi plus tremelimumab did not meet the primary endpoints of improving overall survival compared to standard-of-care chemotherapy in the "hard-to-treat" patients.The safety and tolerability profiles for Imfinzi and the combination with tremelimumab were consistent with previous experience."The prognosis for recurrent or metastatic head and neck squamous cell cancer is very poor and new treatments for this group of cancers are urgently needed," said AstraZeneca's executive vice-president of global medicines development and chief medical officer Sean Bohen."While these results are disappointing, we remain committed to evaluating the potential of Imfinzi and other innovative medicines for patients with head and neck cancer."We look forward to seeing the results of the Phase III KESTREL trial of Imfinzi and tremelimumab in patients who have not received prior chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma in the first half of 2019."AstraZeneca said it would submit the results from the Phase III EAGLE trial for presentation at a forthcoming medical meeting.
More News
9 Feb 2024 07:51
LONDON BRIEFING: Barclays buys Tesco's retail banking business
(Alliance News) - Stocks in London are called to open higher on Friday, closing off a busy corporate week.
Read more8 Feb 2024 17:00
LONDON MARKET CLOSE: Softer earnings weigh on underperforming FTSE 100
(Alliance News) - London's FTSE 100 ended lower on Thursday, with mixed corporate updates keeping a lid on enthusiasm, while in New York the S&P 500 has the 5,000 point mark in touching distance.
Read more8 Feb 2024 14:42
London close: Stocks slip as US jobless claims fall
(Sharecast News) - London markets experienced a downturn in trading on Thursday, with stocks relinquishing earlier gains as investors processed a decrease in jobless claims in the United States.
Read more8 Feb 2024 12:08
LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi
(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.
Read more8 Feb 2024 08:59
LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend
(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.
Read more8 Feb 2024 08:44
TOP NEWS: AstraZeneca confident after 2023 profit more than doubles
(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.
Read more8 Feb 2024 07:58
AstraZeneca shares slip as Q4 profits miss forecasts
(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.
Read more8 Feb 2024 07:50
LONDON BRIEFING: Unilever sets new buyback; Astra profit surges
(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.
Read more2 Feb 2024 08:38
AstraZeneca celebrates latest successful trial of acoramidis in Japan
(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.
Read more2 Feb 2024 06:22
TOP NEWS: US sends drugmakers initial offers in Medicare price talks
(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.
Read more1 Feb 2024 15:52
UK earnings, trading statements calendar - next 7 days
| Friday 2 February | |
| YouGov PLC | Trading Statement |
| Monday 5 February | |
| Home REIT PLC | Trading Statement |
| Porvair PLC | Full Year Results |
| Trident Royalties PLC | Trading Statement |
| Vodafone Group PLC | Trading Statement |
| Tuesday 6 February | |
| Alumasc Group PLC | Half Year Results |
| BP PLC | Full Year Results |
| Filtronic PLC | Half Year Results |
| Mattioli Woods PLC | Half Year Results |
| Renishaw PLC | Half Year Results |
| Virgin Money UK PLC | Trading Statement |
| Wednesday 7 February | |
| Ashmore Group PLC | Half Year Results |
| Barratt Developments PLC | Half Year Results |
| HydrogenOne Capital Growth PLC | Trading Statement |
| Phoenix Spree Deutschland Ltd | Trading Statement |
| PZ Cussons PLC | Half Year Results |
| Smurfit Kappa Group PLC | Full Year Results |
| UK Commercial Property REIT Ltd | Trading Statement |
| Thursday 8 February | |
| Anglo American PLC | Trading Statement |
| AstraZeneca PLC | Full Year Results |
| British American Tobacco PLC | Full Year Results |
| Compass Group PLC | Trading Statement |
| Redrow PLC | Half Year Results |
| SSE PLC | Trading Statement |
| Unilever PLC | Full Year Results |
| Comments and questions to newsroom@alliancenews.com | |
| A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
| Copyright 2024 Alliance News Ltd. All Rights Reserved. | |
29 Jan 2024 08:19
TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US
(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.
Read more22 Jan 2024 11:45
BioNTech challenges AstraZeneca with breast cancer precision drug trial
FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.
Read more19 Jan 2024 09:28
TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH
(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.
Read more